Guillain-Barré Syndrome Following the ChAdOx1-S/nCoV-19 Vaccine: A Case Report
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Serious neurological complications following coronavirus disease 2019 (COVID-19) vaccination, such as cerebral venous sinus thrombosis or acute disseminated encephalomyelitis, have rarely been reported. Here, we report a case of Guillain-Barré syndrome (GBS) that occurred within 2 weeks of receiving the AstraZeneca ChAdOx1-S/nCoV-19 vaccine. A 61-year-old man presented with weakness and hypesthesia of the legs 9 days after the first dose of the ChAdOx1-S vaccine. The patient progressed to respiratory failure and severe quadriparesis. Nerve conduction studies showed markedly reduced amplitudes of compound muscle action potentials and sensory nerve action potentials in both upper and lower extremities, without definitive evidence of demyelination. The patient was diagnosed with axonal GBS and received intravenous immunoglobulin treatment, with a poor response. This is a rare case of GBS after COVID-19 vaccination in Korea. Physicians should be aware of this rare but serious complication of the COVID-19 vaccine to effectively manage such a situation in clinical practice.
Abstract
Serious neurological complications following coronavirus disease 2019 (COVID-19) vaccination, such as cerebral venous sinus thrombosis or acute disseminated encephalomyelitis, have rarely been reported. Here, we report a case of Guillain-Barré syndrome (GBS) that occurred within 2 weeks of receiving the AstraZeneca ChAdOx1-S/nCoV-19 vaccine. A 61-year-old man presented with weakness and hypesthesia of the legs 9 days after the first dose of the ChAdOx1-S vaccine. The patient progressed to respiratory failure and severe quadriparesis. Nerve conduction studies showed markedly reduced amplitudes of compound muscle action potentials and sensory nerve action potentials in both upper and lower extremities, without definitive evidence of demyelination. The patient was diagnosed with axonal GBS and received intravenous immunoglobulin treatment, with a poor response. This is a rare case of GBS after COVID-19 vaccination in Korea. Physicians should be aware of this rare but serious complication of the COVID-19 vaccine to effectively manage such a situation in clinical practice.
참고문헌 (13)
- Kim JH, "Looking beyond COVID-19 vaccine phase 3 trials", Nat Med, 27, pp.205~211 (2021)
- Bae Seongman, "Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea", Journal of Korean Medical Science, 36(17), pp.1~9 (2021), 대한의학회[DOI]
- Huh Kyungmin, "Predicted and Observed Incidence of Thromboembolic Events among Koreans Vaccinated with ChAdOx1 nCoV-19 Vaccine", Journal of Korean Medical Science, 36(27), pp.1~6 (2021), 대한의학회[DOI]
- Maramattom BV, "Guillain-Barré syndrome following ChAdOx1-S", nCoV-19 vaccine, 2021, pp.90, 312~314
- Toscano G, "Guillain-Barré syndrome associated with SARS-CoV-2", N Engl J Med, 382, pp.2574~2576 (2020)
- "Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barré Syndrome (GBS) following adenovirus vector COVID-19 vaccines" (2021)[URL]
- Willison HJ, "Guillain-Barré syndrome", Lancet, 388, pp.717~727 (2016)
- Salmon DA, "Association between Guillain-Barré syndrome and influenza A(H1N1)2009 monovalent inactivated vaccines in the USA : a meta-analysis", Lancet, 381, pp.1461~1468 (2013)
- Lu L, "The potential neurological effect of the COVID-19 vaccines : a review", Acta Neurol Scand, 144, pp.3~12 (2021)
- Dalakas MC, "Guillain-Barré syndrome : the first documented COVID-19-triggered autoimmune neurologic disease : more to come with myositis in the offing", Neurol Neuroimmunol Neuroinflamm, 7, pp.e781~ (2020)
- 김아영, "Epidemiological Features and Economic Burden of Guillain-Barré Syndrome in South Korea: A Nationwide Population-Based Study", Journal of Clinical Neurology, 17(2), pp.257~264 (2021), 대한신경과학회
- Lee H, "Incidence of Guillain-Barré syndrome is not associated with influenza vaccination in the elderly", Vaccines(Basel), 8, pp.431~ (2020)
- James J, "Guillain-Barré syndrome following ChAdOx1 nCoV-19 COVID-19 vaccination : a case series", Neurol Clin Neurosci, 9, pp.402~405 (2021)